In particular, experimental studies investigating the effect of P2RX7 antagonism on pathophysiological activity in PD models, as well as targeted manipulation of HSPD1/HSPA9 in glial cells in cell cultures or cell organoids, are essential to allow the assessment of their impact on brain activity and behavioral/clinical outputs. The gene discussed is HSPD1; the disease is Parkinson disease.